Chief & Presenting Author: Dr.Ruchi Agarwal

Co Author(s): Prof.Sanjiv Kumar Gupta

Abstract

Purpose: To retrospectively evaluate the efficacy and safety profile of intravitreal injection of bevacizumab bio-similar product Zybev(Z) for macular edema because of retinal diseases.
Methods: Patients with macular edema who had been administered intravitreal injections of bio-similar bevacizumab were evaluated for changes in the retinal thickness and visual acuity to judge the efficacy, and safety profile over 6 weeks.
Results: A total of 104 patients were included in the study. The mean pre-injection best corrected visual acuity (BCVA), central subfield thickness (CST), mean average cube thickness and volume decreased over 6 weeks, this change was statistically significant (P < 0.05) for all groups.
Conclusion: This short-term retrospective analysis provides evidence regarding the efficacy and safety of intravitreal injection of bio-similar products of bevacizumab for the treatment of macular edema because of retinal diseases.